Becton Dickinson
Prix: 146.24Entreprise et modèle économique
Becton Dickinson (BDX) is a global medical technology company that develops, manufactures, and sells a broad range of medical devices, instrument systems, and reagents. Its core products include syringes, needles, and blood collection systems, primarily serving healthcare institutions. Major business segments encompass BD Medical, BD Life Sciences, and BD Biosciences, with revenue sources derived from product sales and services in these segments.
Profil d’investissement
The investment profile of Becton Dickinson is more aligned with dividends, given its consistent dividend yield. The stock may appeal to investors seeking income rather than aggressive growth, reflecting a balanced approach. However, recent performance indicators suggest caution, indicating potential risks for investors.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 3.95 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -10.2% ↓
- Surprise BPA
- 31.7% meilleur que prévu
- Volatilité 20 j
- 1.3% stable
- Rendement du dividende
- 2.6% modéré dernière date ex-dividende: 2026-03-10
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-09 03:33 | Conserver | Vendre | Weak fundamentals and negative momentum raise concerns. |
| 2026-06-01 02:32 | Vendre | Conserver | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 15:08 | — | Vendre | Weak fundamentals and negative momentum raise concerns. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-05-11 09:26 | Barclays | Objectif relevé | 202 → 204 | 149.43 |
| 2026-04-17 11:40 | Piper Sandler | Objectif abaissé | 170 → 159 | 154.82 |
| 2026-04-14 11:17 | RBC Capital | Objectif abaissé | 195 → 175 | 155.43 |
Rien pour le moment